It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRIS’s FA Score shows that 0 FA rating(s) are green whileEXEL’s FA Score has 1 green FA rating(s), and FBIO’s FA Score reflects 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRIS’s TA Score shows that 7 TA indicator(s) are bullish while EXEL’s TA Score has 5 bullish TA indicator(s), and FBIO’s TA Score reflects 6 bullish TA indicator(s).
CRIS (@Biotechnology) experienced а +17.19% price change this week, while EXEL (@Biotechnology) price change was -0.61% , and FBIO (@Biotechnology) price fluctuated +14.71% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was +0.51%, and the average quarterly price growth was -5.83%.
CRIS is expected to report earnings on Mar 31, 2025.
EXEL is expected to report earnings on Aug 12, 2025.
FBIO is expected to report earnings on Mar 31, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
CRIS | EXEL | FBIO | |
Capitalization | 23.5M | 11.6B | 57.7M |
EBITDA | -44.56M | 719M | -108.52M |
Gain YTD | -26.471 | 27.928 | -3.704 |
P/E Ratio | N/A | 19.45 | N/A |
Revenue | 10.3M | 2.17B | 62.5M |
Total Cash | 20.9M | 1.11B | 58.9M |
Total Debt | 3.26M | 191M | 71.5M |
CRIS | EXEL | FBIO | ||
---|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 69 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 73 Overvalued | 37 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 30 | 100 | |
SMR RATING 1..100 | 99 | 41 | 98 | |
PRICE GROWTH RATING 1..100 | 65 | 39 | 45 | |
P/E GROWTH RATING 1..100 | 100 | 90 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FBIO's Valuation (37) in the Biotechnology industry is in the same range as CRIS (63) and is somewhat better than the same rating for EXEL (73). This means that FBIO's stock grew similarly to CRIS’s and somewhat faster than EXEL’s over the last 12 months.
EXEL's Profit vs Risk Rating (30) in the Biotechnology industry is significantly better than the same rating for FBIO (100) and is significantly better than the same rating for CRIS (100). This means that EXEL's stock grew significantly faster than FBIO’s and significantly faster than CRIS’s over the last 12 months.
EXEL's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for FBIO (98) and is somewhat better than the same rating for CRIS (99). This means that EXEL's stock grew somewhat faster than FBIO’s and somewhat faster than CRIS’s over the last 12 months.
EXEL's Price Growth Rating (39) in the Biotechnology industry is in the same range as FBIO (45) and is in the same range as CRIS (65). This means that EXEL's stock grew similarly to FBIO’s and similarly to CRIS’s over the last 12 months.
EXEL's P/E Growth Rating (90) in the Biotechnology industry is in the same range as FBIO (100) and is in the same range as CRIS (100). This means that EXEL's stock grew similarly to FBIO’s and similarly to CRIS’s over the last 12 months.
CRIS | EXEL | FBIO | |
---|---|---|---|
RSI ODDS (%) | 2 days ago90% | 2 days ago66% | 2 days ago90% |
Stochastic ODDS (%) | 2 days ago77% | 2 days ago79% | 2 days ago90% |
Momentum ODDS (%) | 2 days ago80% | 2 days ago65% | 2 days ago82% |
MACD ODDS (%) | 2 days ago70% | 2 days ago65% | 2 days ago86% |
TrendWeek ODDS (%) | 2 days ago78% | 2 days ago64% | 2 days ago81% |
TrendMonth ODDS (%) | 2 days ago79% | 2 days ago64% | 2 days ago81% |
Advances ODDS (%) | 2 days ago75% | 16 days ago64% | 2 days ago82% |
Declines ODDS (%) | 24 days ago89% | 8 days ago63% | 10 days ago84% |
BollingerBands ODDS (%) | 2 days ago87% | 2 days ago61% | 2 days ago90% |
Aroon ODDS (%) | 2 days ago89% | 2 days ago56% | 2 days ago81% |
A.I.dvisor indicates that over the last year, CRIS has been loosely correlated with VTGN. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRIS jumps, then VTGN could also see price increases.
Ticker / NAME | Correlation To CRIS | 1D Price Change % | ||
---|---|---|---|---|
CRIS | 100% | +7.66% | ||
VTGN - CRIS | 37% Loosely correlated | +0.79% | ||
ABEO - CRIS | 37% Loosely correlated | +2.84% | ||
CGON - CRIS | 36% Loosely correlated | +3.76% | ||
NUVL - CRIS | 36% Loosely correlated | +4.66% | ||
RARE - CRIS | 35% Loosely correlated | +1.98% | ||
More |
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with ALNY. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then ALNY could also see price increases.
Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
---|---|---|---|---|
EXEL | 100% | +0.45% | ||
ALNY - EXEL | 34% Loosely correlated | +2.57% | ||
JAZZ - EXEL | 34% Loosely correlated | +1.17% | ||
TECH - EXEL | 33% Poorly correlated | +0.83% | ||
MRSN - EXEL | 32% Poorly correlated | -4.62% | ||
ORMP - EXEL | 32% Poorly correlated | +3.24% | ||
More |
A.I.dvisor indicates that over the last year, FBIO has been loosely correlated with AXON. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if FBIO jumps, then AXON could also see price increases.
Ticker / NAME | Correlation To FBIO | 1D Price Change % | ||
---|---|---|---|---|
FBIO | 100% | +2.63% | ||
AXON - FBIO | 38% Loosely correlated | -2.76% | ||
CRBP - FBIO | 38% Loosely correlated | +5.39% | ||
ABOS - FBIO | 35% Loosely correlated | +2.94% | ||
EYPT - FBIO | 34% Loosely correlated | +2.41% | ||
KYTX - FBIO | 33% Poorly correlated | +3.14% | ||
More |